Going beyond protein degradation, a new Broad startup kicks into gear to fix protein functionality
There’s a plethora of protein degradation biotechs, and a smaller handful of protein stabilization players, but Lizzie Ngo was searching for something more.
The principal at Longwood Fund, the investment firm behind the likes of Bicycle Therapeutics, wanted to know, “What else could we do beyond just targeted protein degradation?” she told Endpoints News.
While mapping out the space, she and a colleague came across a 2020 paper from Amit Choudhary’s lab at MIT and Harvard’s Broad Institute. As so many biotechs’ origin stories begin, the paper led to a new startup with ambitions going beyond protein degradation and stabilization and into activation, inactivation and trafficking of proteins.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.